Manufacturing ATMPs ‚Äì moving from approvable to commercial success
KTN and The Future Targeted Healthcare Manufacturing Hub will hold an event on UK advanced therapies innovation landscape, London, 18th September.
Advanced Therapy Medicinal Products (ATMPs) are an exciting class of products that includes gene and cell therapies and which tackle a wide range of diseases. Whilst research and development for these has been ongoing for decades, the first regulatory approvals have only occurred in the last few years. A major challenge for these products is that they require further innovation to make them available for large patient populations, as well as providing commercial success for the companies marketing them.
The Future Targeted Healthcare Manufacturing Hub, in partnership with the Knowledge Transfer Network, will be holding an event to showcase the Hub‚Äôs activities in this area, in addition to companies, Research and Technology Organisations and other stakeholders. This free event will take place on the 18th September 2018 at Woburn House Conference Centre in London. The meeting will focus on the current UK innovation landscape for advanced therapies, in support of enabling gene and cell therapy products to go from approvable to commercially successful. Attendees can also expect to hear about translational research projects in support of manufacturing readiness, as well as a session looking towards future challenges from clinical, regulatory and skills perspectives. The meeting shall enable industry and academia engagement, showcasing research being undertaken by the Hub in collaboration with industry.
To register, please click here.